Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Proton Pump Inhibitors
- Sponsor
- Nantes University Hospital
- Enrollment
- 34000
- Locations
- 1
- Primary Endpoint
- PPI deprescribing
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Deprescribing is defined as "the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing the polypharmacy and improving outcomes". Inappropriate use of proton pump inhibitors (PPI) is associated with severe adverse drug reactions and a major economic impact. Deprescribing should be considered when inappropriate prescription of PPI is identified.
DeprescrIPP is a pragmatic population-based cluster-randomized trial conducted in primary care. It will assess the efficacy and effectiveness of a multi-faceted intervention (on patients and general practitioners) to deprescribe PPI.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General practitioners (GPs):
- •All GPs settled in the 2 departments of Loire-Atlantique and Vendée with more than 100 patients in the year before baseline, will be eligible.
- •Patients:
- •aged over 18 years
- •affiliated to the French health insurance system (CPAM)
- •treated with PPI with more than 300 DDD/year in the year before baseline, estimated with reimbursement databases.
- •whose GP is included in the study
Exclusion Criteria
- •General practitioners (GPs):
- •Participation refusal
- •Patients :
- •Participation refusal
- •Patients at risk of gastroduodenal lesions i.e. treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and over 65 years old or treated with either corticosteroids or anticoagulants or platelet aggregation inhibitors
Outcomes
Primary Outcomes
PPI deprescribing
Time Frame: 12 months
Proportion of patients achieving a 50% decrease in their reimbursement of PPI (Defined Daily Dose (DDD)/year) at the end of the intervention compared to baseline.
Secondary Outcomes
- Attitudes of patients towards deprescribing(12 months)
- GERD symptoms recurrence(12 months)
- Cost-utility analysis(12 months)